Research programme: CNS disorder therapeutics - Anvyl

Drug Profile

Research programme: CNS disorder therapeutics - Anvyl

Alternative Names: AVL 5189; AVL 8168

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anvyl
  • Class Steroids
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators; GABA A alpha 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain injuries; Down syndrome; Epilepsy

Most Recent Events

  • 28 Sep 2016 Research programme: CNS disorder therapeutics - Anvyl is available for licensing as of 28 Sep 2016.
  • 28 Sep 2016 Preclinical trials in Brain injuries in USA (unspecified route)
  • 28 Sep 2016 Preclinical trials in Down syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top